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OBJECTIVES: Cystic Fibrosis (CF) is a life-limiting, genetic disorder that has a tre-
mendous impact on patient’s quality of life (QoL). The goal of this review is to sum-
marize QoL literature in CF and identify instruments utilized to capture QoL data in 
adult patients. METHODS: A comprehensive literature search using PRISMA guide-
lines was conducted from January 2010 to October 2014 using electronic databases 
such as PubMed, Scopus, CINAHL, and Cochrane Reviews. Studies assessing physical, 
psychological, social and spiritual impact on patients with CF were identified. The 
QoL instruments from the studies were identified and a review of their psycho-
metric properties in CF was conducted. The search strategy was limited to studies 
conducted in adult population. Full-text, published articles in the United States and 
Europe were included in the final review. RESULTS: A total of 14 QoL studies in CF 
which utilized 6 validated instruments were identified. Three instruments were dis-
ease-specific (CFQ-R, CF-QOL, and a single item measure) and the remaining three 
were generic instruments (SF-36, EQ-5D, and UK-SIP). CFQ-R was used in 11 studies, 
whereas 3 studies used the CF-QoL. Some important factors that influenced QoL 
in CF were pain, lung function, self-esteem, and ethnicity. Psychometric validation 
included validity (discriminant, convergent, and concurrent validity) and reliability 
testing. Reliability of the instruments was found to be within appropriate ranges 
(CFQ-R: Cronbach’s alpha ≥ 0.70; CF-QOL: Test-Retest > 0.8; and Generic instruments: 
Internal Consistency > 0.8). CONCLUSIONS: Clinical outcomes, patient perception, 
and demographic variables were found to influence QoL in adult CF patients. CFQ-R 
is the most commonly reported QoL instrument in CF. Also, the time constraint 
physicians face in using QoL assessment in clinical practice can be addressed by 
the recently developed single-item, CF-specific QoL questionnaire. Overall, CF has a 
negative impact on the physical, mental, and social aspects of patient’s life.
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OBJECTIVES: Multiple sclerosis (MS) is an autoimmune and inflammatory demy-
elinating disease of the central nervous system, often characterized by relapsing 
episodes of neurologic impairment followed by remissions (relapsing remitting MS). 
In about a third of MS patients, the disease evolves into a progressive course (progres-
sive MS). The objective of this study was to evaluate how health-related quality of life 
(HRQL) was taken into consideration in the evaluation of MS products approved by 
the FDA and the EMA since 1995. METHODS: The websites of the FDA and the EMA 
were explored to identify all MS products approved. All labels and corresponding 
clinical reviews (FDA), summary of product characteristics (SmPC) and assessments 
reports (EMA) were manually retrieved and reviewed for HRQL evaluation. RESULTS: 
Twelve different products (11 INN) were approved: nine by both agencies, one only 
by the EMA, and two only by the FDA. For the products approved by both agencies, 
the same clinical studies were submitted. HRQL was evaluated in seven products. In 
only one case, HRQL evaluation was mentioned, i.e., in the SmPC of interferon beta-1b 
(“No benefit, attributable to […] in quality of life (as measured by FAMS – Functional 
Assessment of MS: Treatment Outcomes Index) was seen”). There was no HRQL men-
tion in the corresponding FDA label for the same product. In four products HRQL was 
evaluated with generic measures (e.g., SF-36 or SF-12). In most cases, it was considered 
as a tertiary /exploratory endpoint. In three products (alemtuzumab, natalizumab, and 
teriflunomide), statistical differences in HRQL endpoints were seen (measured by the 
FAMS and/or the SF-36), but not reported in labels/SmPCs. CONCLUSIONS: HRQL is 
not considered as a key endpoint in the evaluation of MS products. A patient-focused 
drug development initiative in MS could be helpful to enhance development and use 
of HRQL MS-specific measures in clinical trials.
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OBJECTIVES: Spinal muscular atrophy (SMA), the most common fatal genetic dis-
ease among children, is not included in current U.S. mandatory newborn screening 
panel. We assessed how much, if anything, people would pay for testing their new-
borns for SMA, and how test preferences varied depending on immediate treatment 
implications. METHODS: We conducted a population-based willingness-to-pay 
(WTP) online survey. Respondents were asked to imagine being parents of a new-
born. Each respondent was presented with two sets of hypothetical scenarios follow-
ing the SMA screening test: current standard of care (SOC, no treatment available) 
and one of three randomly-assigned treatment scenarios (new treatment available 
to improve functioning, survival, or both). We used a double-bounded, dichotomous-
choice bidding game to elicit WTP for the SMA test, and performed a two-part model 
to estimate median and mean WTP values. RESULTS: 982 adults completed the 
survey. Most people (79%) would prefer to test their newborns for SMA, given cur-
rent SOC. A greater proportion (85%-87%) would pay for the test if SMA treatment 
existed. People expressed a WTP for the test information even without treatment 
(median: $142; mean: $253), and a higher amount if SMA treatment were available 
(median: $161-$182; mean: $270-$297). WTP was highest for scenarios in which 
treatment were available to improve both functioning and survival of the new-
born. Individuals with higher income were more likely to prefer and pay more for 
the test. CONCLUSIONS: Our findings highlight preferences for the SMA newborn 
screening test under various treatment scenarios. Most people would prefer and 
would be willing to pay for the test information, even in the absence of direct treat-
ment options. People perceived the SMA test more valuable if treatment were avail-
able to improve the newborn’s functioning and survival. Future clinical studies are 
needed to determine how early detection may impact long-term patient outcomes.
review of published peer-reviewed studies. METHODS: A literature search was per-
formed in “MEDLINE” and “EMBASE” using search terms “quality of life”, “neuromyeli-
tis optica”, and “Devic’s”. The search was limited to English language. All studies that 
got published before November 2014 were retrieved. Studies that included patients 
with NMO and reported use of validated QoL instrument were considered eligible for 
qualitative analysis. Two independent researchers were involved in study selection 
and data extraction. RESULTS: A total of seven studies met the inclusion criteria. 
All the studies were conducted in different countries: The United states of America, 
United Kingdom, France, Japan, and Argentina. The number of patients included in 
the studies ranged from 18-50. The common QoL instruments used included: Short 
form-36 and different pain severity scores. Three studies used MS patients as the 
comparator while two compared the data with normal subjects. Most studies reported 
that QoL is lower in NMO patients as compared to the ones suffering from MS and is 
much worse than normal subjects. The lower QoL score corresponded with higher 
pain scores in NMO patients as compred to MS patients. CONCLUSIONS: Our review 
showed that NMO patients are associated with higher levels of pain and lower QoL 
scores than MS patients. However, available evidence seems to be insufficient and 
more research is warrented in this context.
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OBJECTIVES: This study compared the quality of life including Physical Component 
Summary (PCS), Mental Component Summary (MCS), Activities of Daily Living (ADL) 
and Instrumental Activities of Daily Living (IADL) in patients with Parkinson’s dis-
ease and other neurodegenerative conditions. METHODS: The study used data from 
2002-2011 Medical Expenditure Panel Survey (MEPS), a nationally representative 
survey of households in the United States, to assess the measures of quality of life 
in neurodegenerative patients. Multivariate regression was used to examine the 
effect of neurodegenerative conditions on PCS, MCS, ADL and IADL after controlling 
for various sociodemographic and clinical characteristics. RESULTS: The weighted 
study population included 320,464 patients with Parkinson’s disease and 476,200 
patients with other neurodegenerative conditions. Participants were aged between 
19 and 85 years (mean = 74.32, SD = 11.36). In unadjusted models, the mean PCS 
was lower in patients with Parkinson’s disease [33.66 (32.81-34.50)] compared to 
other neurodegenerative disorders [35.31 (34.19-36.42)]; however the mean MCS was 
higher in Parkinson patients [45.30 (44.44-46.17)] compared to other neurodegenera-
tive patients [43.93 (42.99-44.87)]. The adjusted PCS in Parkinson’s disease was 2.43 
(95% CI= 0.72, 4.15) points lower than other neurodegenerative conditions. Patients 
with Parkinson’s disease were less likely to seek help for instrumental activities 
(IADL) than other neurodegenerative disorders [OR= 0.68 (0.50, 0.93)]; however the 
ADL was not significantly different in Parkinson’s disease in comparison to other 
neurodegenerative conditions [OR= 0.91 (0.64, 1.28)]. Comorbidities including car-
diovascular diseases, diabetes and cancer were also associated with decline in the 
quality of life among patients with Parkinson’s disease as well as other neurodegen-
erative conditions. CONCLUSIONS: The study found that, patients with Parkinson’s 
disease had lower PCS and were less likely to seek help for IADL when compared to 
other neurodegenerative conditions. The study findings suggest differences among 
neurodegenerative conditions across various dimensions of quality of life measures.
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OBJECTIVES: About 5-10% of the total Parkinson’s population are diagnosed from 
the ages of 21-45 and thus characterized as having Young-Onset Parkinson’s Disease 
(YOPD). Since YOPD is diagnosed during the most productive years of a patient’s life, the 
disease can potentially have a larger impact on quality of life (QoL), in part due to the 
unique psychosocial issues younger patients face. The goal of the review is to (i) identify 
QoL instruments utilized in YOPD and (ii) describe the studies that have utilized these 
instruments. METHODS: A systematic literature search based on PRISMA guidelines 
was conducted from 2004 to 2014 using electronic databases such as Pubmed, Medline, 
Cochrane, and Ovid. QoL instruments validated in the general population as well as 
those validated in Parkinson’s Disease (PD) were included in this review. The search 
was limited to studies using the English language. Studies conducted exclusively on PD 
patients diagnosed after age 50 and review studies, were excluded. RESULTS: A total 
of 10 QoL instruments were identified (5 disease-specific, 1 condition-specific, and 4 
generic). PD-specific instruments included the Parkinson’s Disease Questionnaire-39 
and the Parkinson’s Impact Scale. Although frequently utilized in YOPD patients, all 
instruments were validated in either regular-onset PD patients (initial diagnosis greater 
than 45 years of age) or the general population. The literary search did not yield any 
YOPD-specific QoL instruments. CONCLUSIONS: Different experiences, emotions, and 
psychological issues exist between YOPD and regular-onset PD. Yet, QoL instruments 
validated in PD were commonly utilized in YOPD. Thus, there is a need to create YOPD-
specific QoL instruments to capture the impact of this condition on young patients. 
In addition, the development of new YOPD-specific instruments may allow clinicians 
the opportunity to better understand the complexity of problems in YOPD patients to 
guide appropriate care of their unique condition.
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represented less than 0.5% of Medicaid spending in 2013 so cost-containment strate-
gies targeting triptans could not have had a large impact on the Medicaid budget. 
The large increase in triptan prescriptions in 2010 is suggestive of reduced access to 
these medications for many years by Medicaid beneficiaries. Even prior to generic 
sumatriptan entry in the market, sumatriptan held the highest market share in 
Medicaid. This finding is not necessarily explained by superior safety or effective-
ness relative to the other triptans.
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OBJECTIVES: Specialty tiers under Medicare Part D can require a coinsurance of 
up to 33% for drugs that cost $600 per month or more. This study is the first to 
examine the impact of such high cost sharing on use of disease modifying thera-
pies (DMTs) in Medicare beneficiaries with multiple sclerosis (MS). METHODS: 
Using the 2007-2010 5% Medicare files we identified MS patients (ICD-9-CM 340.
xx) with continuous fee-for-service Part D coverage and potential eligibility for 
DMTs in each year based on evidence of disease activity (any DMT use or relapse 
in previous year [N= 3,975]). Outcomes included any fill, adherence (proportion of 
days covered> = 0.80), and continuous 30-day gap for Part D-covered DMTs in the 
initial coverage limit (ICL) period wherein patients not receiving low-income sub-
sidies (non-LIS) faced specialty tiers (25%-33% coinsurance). Similar outcomes for 
Part B-covered and all DMTs allowed examination of impact on substitution and 
overall use, respectively. LIS patients who faced minimal cost sharing ($3-$5 copay) 
in the Part D ICL period served as controls. Logistic regressions with formulary 
fixed-effects compared outcomes across non-LIS and LIS patients with active MS 
facing the same formulary and utilization management tools (but different cost 
sharing levels) while controlling for a series of patient confounders. RESULTS: In 
comparison to LIS patients, non-LIS patients were significantly less likely to use 
Part D DMTs (odds ratios for any fill= 0.36; adherence= 0.42; gap= 2.54,p< 0.001 for 
all ORs). Non-LIS patients were more likely to use Part B DMTs; however, the higher 
use of Part B DMTs did not fully compensate for the lower use of Part D DMTs. As a 
result, non-LIS patients had lower use of any DMTs during the ICL period (ORs for 
any fill= 1.73, adherence = 0.69; gap OR= 1.68,p< 0.05 for all ORs). CONCLUSIONS: 
Part D specialty tier cost sharing was associated with lower likelihood of filling, 
adherence, and continuation of DMTs.
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OBJECTIVES: Humana implemented a step therapy (ST) policy on pregabalin 
for Medicare and commercial plans effective January 2009, and lifted the policy 
for Medicare plans only in April 2013. This study examined the impact of the 
(ST) on pregabalin utilization and therapeutic alternatives, as well as medical 
expenditures for diabetic peripheral neuropathy (DPN), post herpetic neuralgia 
(PHN), and fibromyalgia (FM). METHODS: An interrupted time series design exam-
ined monthly pharmacy and medical claims during January 2007 – April 2014. 
Segmented regression analyses allowed for two change points: January 2009 and 
April 2013 accounting for policy implementation and lift, respectively. Results 
were reported as the average number of claims per 100,000 members per month 
(P100KMPM) for time trend and level change following ST changes. RESULTS: 
The ST implementation resulted in a statistically significant decrease in prega-
balin use by Medicare members, while its lift resulted in a marginally significant 
increase (level change after ST: -198.2 P100KMPM [P< .001]; level change after lift: 
50.5 P100KMPM [P= .072]) in pregabalin use by Medicare members. There was no 
change over time after the ST implementation or lift. As a comparator, the level 
change for commercial members was -107.3 P100KMPM (P< .001) but remained flat 
following the lift (P= .730). Utilization of anticonvulsants in Medicare, which con-
tains the ST prerequisite therapy gabapentin, saw a consistent increase following 
the implementation of the pregabalin ST (trend change after ST: 11.2 P100KMPM 
[P= 0.032]; level change after lift: 289.5 P100KMPM [P< 0.001]; and trend change 
after lift: -22.1 P100KMPM [P= .002]). Medical expenditures for DPN, PHN, and FM 
among the Medicare population increased throughout the study period, but did 
not appear to be impacted by the pregabalin ST (P= .062, P= .361, P= .778 for DPN, FM 
and PHN respectively for level change following implementation). CONCLUSIONS: 
Humana’s ST edit policy has shifted members away from pregabalin but without 
significant impact on disease-related medical costs.
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OBJECTIVES: Seizure clusters, defined as multiple distinct seizures that occur over a 
24-hour period, are serious medical events that may progress to prolonged seizures 
and status epilepticus. In this retrospective chart review, use of rescue medication, 
associated healthcare resource utilization, and costs of seizure clusters were evalu-
ated. METHODS: An online, retrospective chart review of patients with epilepsy 
and seizure clusters was conducted among 186 US neurologists. Adults (≥ 18 years 
old) who were diagnosed with seizure clusters at least 12 months prior to chart 
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OBJECTIVES: Multiple sclerosis (MS) is a chronic neurological disease associated 
with substantial clinical and socioeconomic burden. MS patients experience increas-
ing levels of disability as their disease progresses and this can represent a major 
cause for reduced work capacity. This study evaluates work productivity using Work 
Productivity and Activity Impairment (WPAI) questionnaire for RRMS and SPMS 
patients across Europe. METHODS: Data were drawn from the Adelphi MS Disease 
Specific Programme, a cross-sectional study of 360 neurologists and 3641 patients 
in France, Germany, Italy, Spain, and the United Kingdom. Patient-reported data 
was available for 881 RRMS patients and 142 SPMS patients. Fisher’s Exact or Chi-
Squared (for categorical outcomes) and Mann-Whitney (for numerical outcomes) 
were used to determine differences between RRMS and SPMS patients. RESULTS: 
Compared with RRMS patients, SPMS patients differ significantly in employment 
status (p< 0.0001); SPMS patients are less likely to be employed in full-time (8.0% 
vs. 50.0 %), part time positions (16.8% vs. 17.8%) or be students (1.8% vs 7.9%), and 
are more likely to be unemployed (15.0% vs. 9.8%), unable to be employed (23.0% vs. 
4.0%), retired (23.0% vs 3.4%) or homemakers (12.4% vs 7.2%). Analyses for the WPAI 
questionnaire included 523 RRMS and 29 SPMS patients. Significant differences were 
observed between RRMS and SPMS patients in absenteeism (22.2% vs. 8.5%; p= 0.034), 
presenteeism (34.4% vs 23.4%; p= 0.021) and overall impairment (42.0% vs 25.7%; 
p= 0.004). SPMS patients have a higher mean percentage of daily activity impairment 
due to MS than RRMS patients (65.00% vs 34.56%; p< 0.0001). CONCLUSIONS: Across 
Europe, SPMS patients experience a higher burden of illness and significantly greater 
magnitude of reduced work productivity than RRMS patients. SPMS patients are less 
likely to be employed full-time, and for those that are employed, work and activity 
impairment are significantly greater in SPMS vs RRMS patients.
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OBJECTIVES: To describe the application and perceived utility of pharmacogenomic 
recommendations among physicians managing a cohort of Medicare patients’ 
chronic medical conditions. METHODS: From January 1 through April 30, 2013, 
genetic results were reviewed from Medicare patients. Demographic data included 
patients’ date of birth, age, ethnicity, gender, medication count, ICD-9-CM diagnosis 
codes, insurance information, and current medications. Patients’ physicians were 
provided with a standardized report, including CYP3A4, CYP3A5, CYP2D6, CYP2C19, 
CYP2C9, VKORC1, MTHFR1298, MTHFR677, Factor V, and Factor II genotypes, pheno-
types, and individualized clinical recommendations. Physicians’ responses to a sur-
vey regarding the use of the recommendations were then summarized. RESULTS: 
One hundred and ninety-five patients, with a mean age of 66 years (59% female) 
and an average of 8.7 medications were reviewed. Seventy-seven percent (144/187) 
of physicians’ responses indicated that the reports were received in a timely man-
ner and 99% (192/194) indicated that they were actionable and easy to understand. 
Forty-one percent (77/186) made a dosing change, 52% (99/192) a medication change, 
and 10% (14/137) a medication therapy duration change. Twenty-five percent (46/183) 
indicated that without the report, no changes would have been made, while 38% 
reflected that their clinical assessment alone would have led to therapy modifi-
cation. CONCLUSIONS: Despite timely receipt and ease of understanding, phy-
sicians appear reluctant to utilize pharmacogenomic recommendations from an 
outside source to make changes to medication dosing, regimen, or duration for 
their patients.
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OBJECTIVES: Following FDA approval of sumatriptan in December 1992, sumatriptan 
and subsequently-approved triptans quickly became first-line anti-migraine thera-
pies. The objective of this study was to describe utilization and reimbursement 
trends for triptans over the last two decades in U.S. Medicaid programs. METHODS: 
Using the national summary file for Medicaid outpatient drug utilization main-
tained by the Centers for Medicare and Medicaid Services, quarterly utilization 
and (pre-rebate) expenditure data from 1993-2013 were extracted for all triptans 
reimbursed for Medicaid beneficiaries. Because data were available at the national 
drug code level, data were collected separately for tablets (including orally disin-
tegrating tablets or ODTs), injections, and sprays. RESULTS: The total number of 
triptan prescriptions increased from 87,348 in 1993 to 1.2 million in 2013, with an 
almost doubling of prescriptions between 2010 and 2011, following the availability of 
a generic version of sumatriptan, which led to the loosening of Medicaid restrictions 
surrounding costly triptan use. In 2013, the share of Medicaid reimbursement ($95.9 
million in total) was 75.1% for tablets (including 18.0% for ODTs), 18.6% for injec-
tions, and 6.3% for sprays. In 2013, average reimbursement per prescription was $54 
for tablets, $246 for ODTs, $351 for injections, and $230 for sprays. From 1993-2013, 
sumatriptan was the most widely prescribed among the triptans, accounting for 
74.8% of all Medicaid prescriptions in 2013. CONCLUSIONS: Spending on triptans 
